John Libbey Eurotext

European Journal of Dermatology

MENU

Autoimmune bullous dermatoses: should we treat the patient or the antibodies? A preliminary study Volume 32, issue 2, March-April 2022

  • [1.] Saschenbrecker S, Karl I, Komorowski L, et al. Serological diagnosis of autoimmune bullous skin diseases. Front Immunol 2019; 10: 1974.
  • [2.] Delavarian Z, Layegh P, Pakfetrat A, Zarghi N, Khorashadizadeh M, Ghazi A. Evaluation of desmoglein 1 and 3 autoantibodies in pemphigus vulgaris: correlation with disease severity. J Clin Exp Dent 2020; 12: e440-5.
  • [3.] Liu Y, Wang Y, Chen X, Jin H, Li L. Factors associated with the activity and severity of bullous pemphigoid: a review. Ann Med 2020; 52: 55-62.
  • [4.] Mohebi F, Tavakolpour S, Teimourpour A, et al. Estimated cut-off values for pemphigus severity classification according to pemphigus disease area index (PDAI), autoimmune bullous skin disorder intensity score (ABSIS), and anti-desmoglein 1 autoantibodies. BMC Dermatol 2020; 20: 13.
  • [5.] Masmoudi W, Vaillant M, Vassileva S, et al. International validation of the bullous pemphigoid disease area index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid. Br J Dermatol 2021; 184: 1106-12.